English   español  
Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/219010
Share/Impact:
Statistics
logo share SHARE logo core CORE   Add this article to your Mendeley library MendeleyBASE

Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE
Exportar a otros formatos:

Title

Long‐circulating drug‐dye‐based micelles with ultrahigh pH‐sensitivity for deep tumor penetration and superior chemo‐photothermal therapy

AuthorsSong, Cunfeng; Li, Yuming; Li, Tianliang; Huang, Zhicheng; Fuente, Jesús M. de la; Ni, Jian; Cui, Daxiang
Issue Date2020
PublisherWiley-VCH
CitationAdvanced Functional Materials 30(11): 1906309 (2020)
AbstractNanocarriers for chemo‐photothermal therapy suffer from insufficient retention at the tumor site and poor penetration into tumor parenchyma. A smart drug‐dye‐based micelle is designed by making the best of the structural features of small‐molecule drugs. P‐DOX is synthesized by conjugating doxorubicin (DOX) with poly(4‐formylphenyl methacrylate‐co‐2‐(diethylamino) ethyl methacrylate)‐b‐polyoligoethyleneglycol methacrylate (P(FPMA‐co‐DEA)‐b‐POEGMA) via imine linkage. Through the π–π stacking interaction, IR780, a near‐infrared fluorescence dye as well as a photothermal agent, is integrated into the micelles (IR780‐PDMs) with the P‐DOX. The IR780‐PDMs show remarkably long blood circulation (t1/2β = 22.6 h). As a result, a progressive tumor accumulation and retention are presented, which is significant to the sequential drug release. Moreover, when entering into a moderate acidic tumor microenvironment, IR780‐PDMs can dissociate into small‐size conjugates and IR780, which obviously increases the penetration depth of drugs, and then improves the lethality to deep‐seated tumor cells. Owing to the high delivery efficiency and superior chemo‐photothermal therapeutic efficacy of IR780‐PDMs, 97.6% tumor growth in the A549 tumor‐bearing mice is suppressed with a low dose of intravenous injection (DOX, 1.5 mg kg−1; IR780, 0.8 mg kg−1). This work presents a brand‐new strategy for long‐acting intensive cancer therapy.
Publisher version (URL)https://doi.org/10.1002/adfm.201906309
URIhttp://hdl.handle.net/10261/219010
DOIhttp://dx.doi.org/10.1002/adfm.201906309
ISSN1616-301X
E-ISSN1616-3028
Appears in Collections:(ICMA) Artículos
Files in This Item:
File Description SizeFormat 
longtherapy.pdf3,6 MBAdobe PDFThumbnail
View/Open
Show full item record
Review this work
 


WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.